Anavex life sciences announces full enrollment of phase 2 study of anavex®3-71 for the treatment of schizophrenia

Study anavex3-71-sz-001 successfully completes enrollment with a total of 71 participants both part a (16 participants) and part b (55 participants) of the placebo-controlled phase 2 study fully enrolled top line data expected in the second half of 2025 new york, may 01, 2025 (globe newswire) -- anavex life sciences corp. ("anavex" or the "company") (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today announced the successful completion of enrollment in its phase 2 clinical study of anavex®3-71 for the treatment of schizophrenia (anavex3-71-sz-001, nct06245213 ). the study has enrolled a total of 71 participants, with 16 participants in part a and 55 participants in part b.
AVXL Ratings Summary
AVXL Quant Ranking